medic
care
taiwan
provid
taiwan
nation
health
insur
nhi
sinc
system
cover
taiwan
inhabit
medic
expens
relat
inpati
outpati
emerg
care
chines
medicin
dental
servic
administr
reimburs
purpos
bureau
nhi
audit
patient
diagnosi
procedur
medic
data
ensur
correct
code
appropri
data
record
store
nhird
describ
detail
previou
examin
oad
use
among
patient
extract
longitudin
cohort
diabet
patient
dataset
nhird
dataset
includ
avail
medic
registri
data
patient
incid
per
year
period
studi
exempt
full
review
institut
review
board
taipei
citi
hospit
use
deidentifi
secondari
claim
data
releas
nhird
research
purpos
nationwid
populationbas
studi
assembl
cohort
patient
receiv
new
diagnos
diabet
market
inhibitor
approv
taiwan
definit
diabet
base
presenc
one
primari
discharg
diagnosi
diabet
intern
classif
diseas
ninth
revis
clinic
modif
code
two
ambulatori
visit
diagnosi
diabet
code
use
antidiabet
drug
accuraci
code
dm
diagnos
nhird
date
cohort
entri
first
day
patient
fulfil
diabet
diagnost
criteria
cohort
entri
individu
requir
least
year
old
baselin
medic
histori
least
year
ie
avail
nhird
data
use
verif
purpos
exclud
hospit
sepsi
cohort
entri
subject
follow
outcom
hospit
sepsi
death
loss
follow
end
studi
period
decemb
oad
exposur
may
timedepend
properti
associ
sepsi
occurr
conduct
nest
casecontrol
analysi
estim
odd
ratio
or
sepsi
compar
oad
user
nonus
drug
case
patient
hospit
sepsi
defin
primari
diagnosi
septicemia
code
plu
prescript
antibiot
studi
period
previous
valid
accuraci
definit
index
date
day
case
hospit
admiss
case
randomli
select
control
match
accord
age
year
sex
month
year
cohort
entri
level
urban
monthli
incom
charlson
comorbid
index
adapt
diabet
complic
sever
index
adcsi
durat
follow
oad
prescript
subject
year
index
date
identifi
oad
primari
interest
present
studi
metformin
sulfonylurea
tzd
meglitinid
inhibitor
given
preclin
found
glibenclamid
may
antiinflammatori
respons
sulfonylurea
stratifi
sulfonylurea
glibenclamid
nonglibenclamid
sulfonylurea
oad
prescript
collect
follow
inform
dispens
date
drug
type
quantiti
durat
drug
suppli
pattern
oad
use
categor
current
index
date
recent
day
index
date
past
day
index
date
baselin
demograph
characterist
cohort
analyz
use
descript
statist
conduct
condit
logist
regress
adjust
potenti
confound
factor
includ
oad
use
insulin
use
predefin
comorbid
associ
risk
sepsi
tabl
or
comput
compar
oad
exposur
case
control
microsoft
sql
server
microsoft
corp
redmond
washington
usa
use
data
linkag
process
sampl
analys
perform
use
stata
statist
softwar
version
statacorp
colleg
station
texa
usa
statist
signific
defin
p
total
case
match
control
identifi
tabl
show
baselin
characterist
hypertens
heart
failur
cerebrovascular
diseas
drug
abus
preval
among
case
among
control
tabl
present
crude
adjust
or
develop
sepsi
requir
hospit
case
associ
oad
use
compar
control
adjust
potenti
confound
tabl
metformin
use
associ
decreas
odd
develop
sepsi
adjust
confid
interv
ci
p
wherea
sulfonylurea
adjust
ci
p
meglitinid
adjust
ci
p
use
associ
increas
odd
develop
sepsi
tabl
addit
time
oad
use
may
relat
onset
sepsi
adjust
or
sepsi
ci
current
metformin
use
ci
recent
metformin
use
ci
past
metformin
use
neither
current
sulfonylurea
use
adjust
ci
recent
adjust
ci
sulfonylurea
use
significantli
increas
risk
sepsi
result
remain
similar
sulfonylurea
classifi
either
glibenclamid
nonglibenclamid
supplementari
tabl
current
adjust
ci
recent
adjust
ci
tzd
use
significantli
decreas
risk
sepsi
comparison
metforminbas
combin
therapi
versu
metformin
alon
risk
sepsi
summar
tabl
decreas
risk
sepsi
consist
observ
patient
take
metformin
alon
adjust
ci
metforminbas
combin
therapi
sulfonylurea
adjust
ci
tzd
adjust
ci
inhibitor
adjust
ci
meglitinid
adjust
ci
knowledg
first
populationbas
nest
casecontrol
studi
examin
relationship
oad
use
risk
hospit
sepsi
found
metformin
use
associ
reduc
risk
sepsi
compar
nonus
contrast
meglitinid
sulfonylurea
associ
increas
risk
futur
sepsi
event
associ
evid
among
recent
current
sulfonylurea
user
effect
inhibitor
tzd
sepsi
neutral
reduc
risk
sepsi
occurr
observ
recentcurr
tzd
user
nevertheless
metforminbas
oad
confer
persist
benefit
rate
hospit
sepsi
invitro
studi
found
metformin
treatment
inhibitori
effect
mediat
sepsi
limit
respiratori
staphylococcu
aureu
infect
attenu
hepat
b
viru
similar
find
swedish
populationbas
cohort
mean
followup
period
year
demonstr
metformin
treatment
associ
reduc
risk
composit
outcom
acidosisseri
infect
adjust
hazard
ratio
ci
patient
independ
glycem
control
compar
receiv
oad
sulfonylurea
although
relev
guidelin
diabet
treatment
suggest
withdraw
metformin
patient
sepsi
due
concern
metforminassoci
lactic
approach
controversi
proven
evid
support
increas
risk
condit
among
metformin
user
compar
user
singlecent
retrospect
cohort
studi
patient
septic
emerg
depart
event
signific
improv
shortterm
surviv
sepsi
note
patient
receiv
metformin
compar
p
nationwid
studi
provid
evid
support
associ
metformin
prescript
decreas
risk
sepsi
examin
pattern
past
recent
current
use
furthermor
meglitinid
prescript
opposit
effect
sepsi
develop
appear
weaker
sulfonylurea
user
although
investig
mechan
respons
relationship
beyond
scope
present
studi
propens
insulin
secretagogu
inhibit
adenosin
potassium
channel
pancreat
cell
may
also
effect
found
relat
impair
immun
respons
invad
pathogen
preclin
recentcurr
past
tzd
prescript
associ
modest
reduct
sepsi
risk
suggest
effect
immedi
random
control
trial
rct
investig
clinic
effect
addon
tzd
therapi
patient
show
signific
differ
addit
infect
risk
tzd
group
activ
control
consist
find
present
studi
modest
potenti
benefit
tzd
sepsi
onset
may
offset
intentiontotreat
analys
conduct
rct
patient
lost
follow
withdrew
medic
followup
period
contrast
trial
show
tzd
use
associ
greater
risk
upper
lower
respiratorytract
infect
low
overal
event
rate
sepsi
differ
followup
period
year
among
trial
may
affect
accuraci
estim
incid
sepsi
event
associ
inhibitor
sepsi
risk
observ
present
studi
inhibit
may
pleiotrop
effect
modul
immun
respons
bind
receptor
immun
culprit
pathogen
coronaviru
hepat
c
balanc
immun
inhibit
antiinflamm
may
respons
infect
risk
inhibitor
user
context
weigh
pro
con
inhibitor
use
given
effect
drug
immun
function
result
show
insignific
influenc
sepsi
risk
nest
control
studi
base
world
health
organ
show
inhibitor
use
associ
greater
risk
infect
compar
metformin
use
howev
result
interpret
caution
imprecis
definit
infect
base
spontan
report
introduc
report
bia
strength
present
studi
includ
analysi
larg
case
control
group
respect
repres
nationwid
diabet
popul
previous
receiv
oad
either
without
sepsi
thu
minim
referr
bia
addit
investig
whether
impact
oad
occurr
sepsi
immedi
persist
time
consid
oad
exposur
interv
still
studi
potenti
limit
first
retrospect
observ
natur
causal
could
establish
second
diagnosi
diabet
sepsi
base
cm
code
may
introduc
misclassif
bia
howev
bia
could
nondifferenti
robust
agreement
diagnos
establish
code
clinic
criteria
demonstr
third
claim
databas
includ
individu
baselin
data
glycem
control
level
nonetheless
impact
oad
sepsi
outcom
mainli
result
glucoselow
effect
tendenc
or
differ
oad
tend
toward
coher
therefor
unlik
unmeasur
confound
bias
result
effect
minim
adjust
adcsi
score
lastli
data
potenti
confound
obes
smoke
habit
alcohol
consumpt
also
unavail
databas
conclus
metformin
recent
current
tzd
use
invers
associ
sepsi
occurr
wherea
meglitinid
use
posit
associ
sepsi
occurr
patient
predispos
infect
direct
impact
oad
futur
sepsi
event
consid
cite
articl
shih
cj
et
al
associ
use
oral
antidiabet
drug
risk
sepsi
nest
casecontrol
studi
sci
rep
doi
